当前针对丙型肝炎病毒的治疗方法。

Current therapeutics against HCV.

作者信息

Bhattacharjee Chayan, Singh Maitri, Das Debisukti, Chaudhuri Sujit, Mukhopadhyay Aparna

机构信息

Department of Life Science, Presidency University, 86/1 College Street, Kolkata, 700073 India.

AMRI Hospitals, Salt Lake, Kolkata, India.

出版信息

Virusdisease. 2021 Jun;32(2):228-243. doi: 10.1007/s13337-021-00697-0. Epub 2021 Jul 15.

DOI:10.1007/s13337-021-00697-0

PMID:34307769

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8279913/

Abstract

UNLABELLED

Hepatitis C is a positive stranded enveloped RNA virus belonging to the family. HCV infection leads to severe liver diseases, cirrhosis and hepatocellular carcinoma worldwide. Although treatments have been available for a while, due to its complexity and genetic diversity, only few are reported to be effective against all HCV genotypes. Here, we review the HCV life cycle and its immunogenic potential and various mechanisms via which the virus interferes in the signalling process. A comprehensive overview of current anti-HCV therapeutics, such as, Direct Acting Antiviral (DAA) as well as Host Targeting Agents (HTA), along with their scope, known mechanism of action and limitations are presented.

SUPPLEMENTARY INFORMATION

The online version contains supplementary material available at 10.1007/s13337-021-00697-0.

摘要

未标注

丙型肝炎病毒是一种属于该科的正链包膜RNA病毒。丙型肝炎病毒感染在全球范围内导致严重的肝脏疾病、肝硬化和肝细胞癌。尽管治疗方法已经存在了一段时间，但由于其复杂性和基因多样性，据报道只有少数方法对所有丙型肝炎病毒基因型有效。在这里，我们回顾了丙型肝炎病毒的生命周期及其免疫原性潜力，以及病毒干扰信号传导过程的各种机制。本文全面概述了当前的抗丙型肝炎病毒疗法，如直接作用抗病毒药物（DAA）以及宿主靶向药物（HTA），以及它们的适用范围、已知作用机制和局限性。